Cargando…
Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vacc...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/ https://www.ncbi.nlm.nih.gov/pubmed/34848673 http://dx.doi.org/10.12659/MSM.935624 |
_version_ | 1784610608255074304 |
---|---|
author | Parums, Dinah V. |
author_facet | Parums, Dinah V. |
author_sort | Parums, Dinah V. |
collection | PubMed |
description | In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19. |
format | Online Article Text |
id | pubmed-8647456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86474562021-12-30 Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 Parums, Dinah V. Med Sci Monit Editorial In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19. International Scientific Literature, Inc. 2021-12-01 /pmc/articles/PMC8647456/ /pubmed/34848673 http://dx.doi.org/10.12659/MSM.935624 Text en © Med Sci Monit, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Editorial Parums, Dinah V. Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title | Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title_full | Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title_fullStr | Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title_full_unstemmed | Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title_short | Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 |
title_sort | editorial: sars-cov-2 vaccine responses and breakthrough covid-19 |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/ https://www.ncbi.nlm.nih.gov/pubmed/34848673 http://dx.doi.org/10.12659/MSM.935624 |
work_keys_str_mv | AT parumsdinahv editorialsarscov2vaccineresponsesandbreakthroughcovid19 |